Summary of Study ST001982
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001258. The data can be accessed directly via it's Project DOI: 10.21228/M83M69 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001982 |
Study Title | Lipidomic characterization of Candida albicans in response to Aureobasidin treatment in vitro. |
Study Summary | Candida albicans is an opportunistic yeast pathogen that causes a wide range of infections especially amongst immunocompromised patients. Aureobasidin A (AbA) has been shown to inhibit inositolphosphoryl ceramide synthase (IPCS), a key enzyme responsible for sphingolipid biosynthesis. There are limited studies exploring IPCS as a target molecule for antifungal treatment. It is hypothesized that the mechanism of AbA inhibition involves alteration of C. albicans phospholipid and sphingolipid profiles. The profiling of C. albicans phospholipid and sphingolipid upon exposure to 0.5-4 µg/ml of AbA were determined using Liquid chromatography-mass spectrometry (LC-MS). |
Institute | University of Malaya |
Last Name | Hamdan |
First Name | Nur Wahida |
Address | Jalan Profesor Diraja Ungku Aziz, 50603 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia |
nurwahidahamdan@siswa.um.edu.my | |
Phone | 0193354272 |
Submit Date | 2021-09-16 |
Num Groups | 5 |
Total Subjects | Duplicates |
Num Males | NA |
Num Females | NA |
Analysis Type Detail | LC-MS |
Release Date | 2021-11-22 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001258 |
Project DOI: | doi: 10.21228/M83M69 |
Project Title: | Lipidomic characterization of Candida albicans in response to Aureobasidin treatment in vitro. |
Project Summary: | Candida albicans is an opportunistic yeast pathogen that causes a wide range of infections especially amongst immunocompromised patients. Aureobasidin A (AbA) has been shown to inhibit inositolphosphoryl ceramide synthase (IPCS), a key enzyme responsible for sphingolipid biosynthesis. There are limited studies exploring IPCS as a target molecule for antifungal treatment. It is hypothesized that the mechanism of AbA inhibition involves alteration of C. albicans phospholipid and sphingolipid profiles. The profiling of C. albicans phospholipid and sphingolipid upon exposure to 0.5-4 µg/ml of AbA were determined using Liquid chromatography-mass spectrometry (LC-MS). |
Institute: | University of Malaya |
Department: | Medical Microbiology Department |
Laboratory: | Lab 3 |
Last Name: | Hamdan |
First Name: | Nur Wahida |
Address: | Jalan Profesor Diraja Ungku Aziz, 50603 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia |
Email: | nurwahidahamdan@siswa.um.edu.my |
Phone: | 0193354272 |
Funding Source: | FRGS(FP035-2014A), UM PPP(PG178-2015B) |